remdesivir in COVID-19 mild to moderate - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results GS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50]
GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86]
0.65 [0.21 ; 2.01 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 784 moderate not evaluable deathsdetailed results GS-US-540-5773 (Goldman), 2020 (REV) 1.37 [0.69; 2.72]
GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
1.12 [0.62 ; 2.01 ] GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,193 moderate not evaluable deaths (time to event analysis only)detailed results GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40]
GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84]
0.64 [0.21 ; 1.98 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 796 moderate not evaluable clinical improvementdetailed results GS-US-540-5773 (Goldman), 2020 (REV) 1.27 [0.98; 1.63]
GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74]
GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49]
1.31 [1.09 ; 1.59 ] GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,193 moderate not evaluable clinical improvement (14-day)detailed results GS-US-540-5773 (Goldman), 2020 (REV) 0.65 [0.44; 0.98]
GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47]
GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44]
1.17 [0.65 ; 2.11 ] GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 82% 1,181 moderate not evaluable clinical improvement (28-day)detailed results GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42]
GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17]
1.81 [1.19 ; 2.76 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 784 moderate not evaluable clinical improvement (7-day)detailed results GS-US-540-5773 (Goldman), 2020 (REV) 0.69 [0.45; 1.05]
GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53]
GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09]
1.00 [0.67 ; 1.50 ] GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 66% 1,181 moderate not evaluable clinical improvement (time to event analysis only)detailed results GS-US-540-5773 (Goldman), 2020 (REV) 1.27 [0.98; 1.63]
GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44]
GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42]
1.18 [1.04 ; 1.35 ] GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,193 moderate not evaluable mechanical ventilationdetailed results GS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30]
GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45]
0.20 [0.03 ; 1.16 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 784 moderate not evaluable recoverydetailed results GS-US-540-5773 (Goldman), 2020 (REV) 1.23 [0.97; 1.57]
GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37]
GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45]
1.17 [1.03 ; 1.33 ] GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 3 0% 1,193 moderate not evaluable serious adverse eventsdetailed results GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23]
GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14]
0.53 [0.30 ; 0.94 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 0% 784 moderate not evaluable adverse eventsdetailed results GS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42]
GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80]
1.40 [1.05 ; 1.87 ] GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020 2 4% 784 moderate not evaluable serious adverse events (SAE), anydetailed results GS-US-540-5773 (Goldman), 2020 (REV) 1.98 [1.27; 3.11]
1.98 [1.27 ; 3.11 ] GS-US-540-5773 (Goldman), 2020 (REV) 1 0% 397 NA not evaluable 0.0 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:56 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 90
- treatments: 510
- roots T: 290